Focus-X Therapeutics, founded in 2020, is a preclinical stage biotechnology company committed to the discovery and development of cutting-edge radiopharmaceuticals. We focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with very low five-year survival rate. We bring our proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to breakdown cancer cell DNA. As an emerging leader of RLT, our mission is to release the true potential of such modality by leveraging our world-class peptide drug discovery platform and joining force with top radiopharmaceutical partners.